Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 2, 2026, 5:52 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–13 of 13 matching trials from the live ClinicalTrials.gov search.
Filters: Sponsor: Genome & Company Clear all
Completed Phase 1 Interventional

GEN-001 (Live Biotherapeutic Product) and Avelumab Combination Study for Patients With Solid Tumors Who Have Progressed on Anti-PD-(L)1 Therapy

NCT04601402
View directory record Official record
Conditions
Solid Tumor, Non Small Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck, Urothelial Carcinoma
Interventions
GEN-001, Avelumab
Drug
Lead sponsor
Genome & Company
Industry
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
3
States / cities
New Haven, Connecticut • Atlanta, Georgia • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Aug 8, 2023 · Synced Oct 2, 2026, 5:52 AM EDT
Completed Phase 2 Interventional Results available

Pediatric Lupus Trial of Belimumab Plus Background Standard Therapy

NCT01649765
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Belimumab 10 mg/kg, Placebo
Drug · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
5 Years to 17 Years
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2025
U.S. locations
7
States / cities
Phoenix, Arizona • Washington D.C., District of Columbia • Augusta, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Oct 2, 2026, 5:52 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Belimumab in Patients With Active Lupus Nephritis

NCT01639339
View directory record Official record
Conditions
Lupus Nephritis
Interventions
Placebo plus standard therapy, Belimumab 10 mg/kg plus standard therapy, Standard therapy
Biological · Drug
Lead sponsor
Human Genome Sciences Inc., a GSK Company
Industry
Eligibility
18 Years and older
Enrollment
448 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
17
States / cities
La Palma, California • San Leandro, California • Torrance, California + 13 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2021 · Synced Oct 2, 2026, 5:52 AM EDT
Completed Phase 4 Interventional Results available

Efficacy and Safety of Belimumab in Black Race Patients With Systemic Lupus Erythematosus (SLE)

NCT01632241
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Placebo plus standard therapy, Belimumab 10 mg/kg plus standard therapy, Standard therapy
Biological · Drug
Lead sponsor
Human Genome Sciences Inc., a GSK Company
Industry
Eligibility
18 Years and older
Enrollment
503 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
64
States / cities
Birmingham, Alabama • Covina, California • La Palma, California + 49 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2021 · Synced Oct 2, 2026, 5:52 AM EDT
Completed Phase 3 Interventional Results available

A Continuation Trial for Subjects With Lupus Who Completed Protocol HGS1006-C1056 in the United States

NCT00724867
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Belimumab 1 mg/kg, Belimumab 10 mg/kg
Biological
Lead sponsor
Human Genome Sciences Inc., a GSK Company
Industry
Eligibility
18 Years and older
Enrollment
268 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
51
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 43 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2016 · Synced Oct 2, 2026, 5:52 AM EDT
Completed Phase 3 Interventional Results available

Belimumab in Remission of VASculitis

NCT01663623
View directory record Official record
Conditions
Vasculitis
Interventions
Placebo, Belimumab 10 mg/kg, Azathioprine
Biological · Drug
Lead sponsor
Human Genome Sciences Inc., a GSK Company
Industry
Eligibility
18 Years and older
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
22
States / cities
Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 18 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2018 · Synced Oct 2, 2026, 5:52 AM EDT
Suspended Phase 1 Interventional

A Study of HGS1036 in Combination With Chemotherapy in Subjects With Advanced Solid Malignancies

NCT01604863
View directory record Official record
Conditions
Cancer
Interventions
HGS1036 + Paclitaxel + Carboplatin, HGS1036 + Cisplatin + Etoposide, HGS1036 + Docetaxel
Drug
Lead sponsor
Human Genome Sciences Inc., a GSK Company
Industry
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
2
States / cities
Scottsdale, Arizona • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 1, 2012 · Synced Oct 2, 2026, 5:52 AM EDT
Completed Phase 4 Interventional Results available

A Study to Evaluate the Effect of Belimumab on Vaccine Responses in Subjects With Systemic Lupus Erythematosus (SLE)

NCT01597492
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Belimumab plus Early Vaccination, Belimumab plus Late Vaccination
Biological
Lead sponsor
Human Genome Sciences Inc., a GSK Company
Industry
Eligibility
18 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
15
States / cities
Birmingham, Alabama • Paradise Valley, Arizona • Shreveport, Louisiana + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 16, 2018 · Synced Oct 2, 2026, 5:52 AM EDT
No Longer Available No phase listed Expanded access

Expanded Access Trial of Belimumab Antibody in RA Patients Who Were Previously Treated Under HGS Protocol LBRA99

NCT00931086
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
belimumab
Drug
Lead sponsor
Human Genome Sciences Inc., a GSK Company
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Oct 31, 2012 · Synced Oct 2, 2026, 5:52 AM EDT
Completed Phase 2 Interventional Results available

A Continuation Trial for Subjects With Systemic Lupus Erythematosus That Have Completed Protocol LBSL02

NCT00583362
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Belimumab
Biological
Lead sponsor
Human Genome Sciences Inc., a GSK Company
Industry
Eligibility
18 Years and older
Enrollment
298 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2016
U.S. locations
56
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 48 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2019 · Synced Oct 2, 2026, 5:52 AM EDT
Completed Phase 1 Interventional

A Study of Mapatumumab in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma

NCT00712855
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
mapatumumab, sorafenib
Biological · Drug
Lead sponsor
Human Genome Sciences Inc., a GSK Company
Industry
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
6
States / cities
Los Angeles, California • Aurora, Colorado • Gainesville, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2012 · Synced Oct 2, 2026, 5:52 AM EDT
Completed Phase 3 Interventional Results available

A Study of Belimumab Administered Subcutaneously in Subjects With Systemic Lupus Erythematosus (SLE)

NCT01484496
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Placebo, Belimumab 200 mg SC, Standard therapy
Biological · Drug
Lead sponsor
Human Genome Sciences Inc., a GSK Company
Industry
Eligibility
18 Years and older
Enrollment
839 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
82
States / cities
Birmingham, Alabama • Peoria, Arizona • Tucson, Arizona + 68 more
Source: ClinicalTrials.gov public record
Updated Jun 6, 2018 · Synced Oct 2, 2026, 5:52 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of Mapatumumab in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma

NCT01258608
View directory record Official record
Conditions
Carcinoma, Hepatocellular
Interventions
Mapatumumab, Placebo, Sorafenib
Drug
Lead sponsor
Human Genome Sciences Inc., a GSK Company
Industry
Eligibility
18 Years and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
9
States / cities
Aurora, Colorado • Shreveport, Louisiana • Rochester, Minnesota + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2018 · Synced Oct 2, 2026, 5:52 AM EDT